Amarin's Vascepa misses primary endpoint in Phase 3 colorectal cancer trial
Bitget2026/10/25 12:11- Amarin reported Phase 3 EMT2 results showing VAZKEPA/VASCEPA missed its primary goal of delaying cancer progression but improved overall survival.
- The University of Leeds-sponsored trial evaluated adjunctive treatment in colorectal cancer patients undergoing surgery for liver metastases.
- Results were presented at the European Society for Medical Oncology 2026 Congress in Madrid.
- Treatment was well tolerated, with no excess adverse events or meaningful deterioration in quality of life versus placebo.
- The findings support further evaluation of the cardiovascular drug’s potential use in cancer care.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
HBAR Price Eyes $0.155 as Traders Watch Key Recovery Levels
Microsoft Beats Nvidia for the First Time Since 2025: So Why Is MSFT Stock Falling?
Gunnison hits rich copper and zinc in Arizona
EIA expects Brent crude spot prices to remain at $100 per barrel for the rest of the year and raises the average price forecasts for this year and next.
The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.
Crypto prices
More
